Oxymetazoline Hydrochloride 1% Cream (Rhofade) for Persistent Facial Erythema Associated with Rosacea
Garcia, C.; Birch, M.
American Family Physician 97(12): 808-810
2018
ISSN/ISBN: 0002-838X PMID: 30216014 Document Number: 695275
Document emailed within 1 workday
Related Documents
Tanghetti, E.A.; Dover, J.S.; Goldberg, D.J.; Dhawan, S.S.; Luo, L.; Berk, D.R.; Ahluwalia, G.; Alvandi, N. 2018: Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the first day of Treatment with Oxymetazoline Cream 1.0 Journal of Drugs in Dermatology: Jdd 17(6): 621-626Stein-Gold, L.; Kircik, L.; Draelos, Z.D.; Werschler, P.; DuBois, J.; Lain, E.; Baumann, L.; Goldberg, D.; Kaufman, J.; Tanghetti, E.; Ahluwalia, G.; Alvandi, N.; Weng, E.; Berk, D. 2018: Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated with Rosacea: Pooled Analysis of the two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials Journal of Drugs in Dermatology: Jdd 17(11): 1201-1208
Baumann, L.; Goldberg, D.J.; Stein Gold, L.; Tanghetti, E.A.; Lain, E.; Kaufman, J.; Weng, E.; Berk, D.R.; Ahluwalia, G. 2018: Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated with Rosacea: Findings from the Second REVEAL Trial Journal of Drugs in Dermatology: Jdd 17(3): 290-298
Kircik, L.H.; DuBois, J.; Draelos, Z.D.; Werschler, P.; Grande, K.; Cook-Bolden, F.E.; Weng, E.; Berk, D.R.; Ahluwalia, G. 2018: Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated with Rosacea: Findings from the first REVEAL Trial Journal of Drugs in Dermatology: Jdd 17(1): 97-105
Tirlapur, V.G.; Rice-Oxley, J.M. 1981: Facial erythema and telangiectasia with synalar cream British Journal of Clinical Practice 35(7-8): 275-276
Moore, A.; Kempers, S.; Murakawa, G.; Weiss, J.; Tauscher, A.; Swinyer, L.; Liu, H.; Leoni, M. 2014: Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study Journal of Drugs in Dermatology: Jdd 13(1): 56-61
Fowler, J.; Jackson, M.; Moore, A.; Jarratt, M.; Jones, T.; Meadows, K.; Steinhoff, M.; Rudisill, D.; Leoni, M. 2013: Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies Journal of Drugs in Dermatology: Jdd 12(6): 650-656
Stanisz, B. 2002: The stability of oxymetazoline hydrochloride in aqueous solution Acta Poloniae Pharmaceutica 59(1): 19-23
Shalita, A.; Miller, B.; Menter, A.; Abramovits, W.; Loven, K.; Kakita, L. 2005: Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study Journal of Drugs in Dermatology: Jdd 4(2): 153-158
Schlesinger, T.E.; Powell, C.R. 2013: Efficacy and tolerability of low molecular weight hyaluronic acid sodium salt 0.2% cream in rosacea Journal of Drugs in Dermatology: Jdd 12(6): 664-667
Gold, L.S.; Papp, K.; Lynde, C.; Lain, E.; Gooderham, M.; Johnson, S.; Kerrouche, N. 2017: Treatment of Rosacea with Concomitant use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: a Randomized, Vehicle-controlled Study Journal of Drugs in Dermatology: Jdd 16(9): 909-916
Poljacki, M.; Duran, V.; Vucković, N.; Subotić, M.; Ivkov, M.; Matić, M.; Jovanović, M. 1999: Persistent dyschromic erythema Medicinski Pregled 52(3-5): 165-168
Wanner, M.; Pol-Rodriguez, M.; Hinds, G.; Hutt, C.; Husain, S.; Grossman, M.E. 2007: Persistent erythema multiforme and CMV infection Journal of Drugs in Dermatology: Jdd 6(3): 333-336
Signore, R.J. 1995: A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea Cutis 56(3): 177-179
Hoffman, L.D.; Hoffman, M.D. 2006: Dapsone in the treatment of persistent erythema multiforme Journal of Drugs in Dermatology: Jdd 5(4): 375-376
Fuchs, D.; Querings, K.; Burg, G.; Böni, R. 1999: Persistent erythema after total CO2 skin resurfacing Schweizerische Medizinische Wochenschrift 129(21): 813-817
Paukstadt, W. 2005: Always consider complications in facial erythema MMW Fortschritte der Medizin 147(41): 15-16
Stevanović, D.V. 1971: Investigation on the effect on skin healing of a cream containing dexamethasone, chlorhexidine hydrochloride and nandrolone decanoate Arzneimittel-Forschung 21(8): 1225-1227
Conejo-Mir, J.S.; del Canto, S.; Muñoz, M.Angel.; Rodríguez-Freire, L.; Serrano, A.; Hernandez, C.; Pulpillo, A. 2003: Thalidomide as elective treatment in persistent erythema multiforme; report of two cases Journal of Drugs in Dermatology: Jdd 2(1): 40-44
Lee, C.S.; Koo, J. 2009: The efficacy of three class i topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison Journal of Drugs in Dermatology: Jdd 8(8): 751-755